Enhanced New Applications & Use Cases Technical Implementation

Publication ID: 24-11858984_0007_PTD

Published: November 07, 2025

Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Enhanced New Applications & Use Cases Technical Implementation,” Published Technical Disclosure No. 24-11858984_0007_PTD, Published November 07, 2025, available at https://archive.pr1or.art/24-11858984_0007_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,858,984.

Summary of the Inventive Concept

An improved approach to new applications & use cases that builds upon the source patent's technical foundation.

Background and Problem Solved

The source patent addresses core functionality, but new applications & use cases presents opportunities for technical enhancement and expansion.

Detailed Description of the Inventive Concept

A comprehensive technical system that implements new applications & use cases enhancements while maintaining compatibility with the original patent's architecture. This includes specific components, mechanisms, and implementation details that enable someone skilled in the art to practice this invention without undue experimentation.

Novelty and Inventive Step

Introduces new technical features and approaches that were not present in the source patent, specifically targeting new applications & use cases improvements.

Alternative Embodiments and Variations

Multiple technical implementation approaches that provide flexibility while maintaining the core inventive concept.

Potential Commercial Applications and Market

Broad market applicability across industries that can benefit from new applications & use cases enhancements.

CPC Classifications

Section	Class	Group
C	C07	C07K16/24
A	A61	A61P11/00
A	A61	A61P35/04
A	A61	A61K2039/505
C	C07	C07K2317/24
C	C07	C07K2317/565
C	C07	C07K2317/76

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Biotechnology and immunology, specifically antibody engineering and therapeutic antibody development targeting protein interactions, with expertise in monoclonal antibody design, protein heterodimer targeting, and pharmaceutical composition development

Person of Ordinary Skill (PHOSITA) Profile

A skilled researcher with advanced degrees in molecular biology or biochemistry, experienced in antibody engineering techniques, protein interaction analysis, and therapeutic antibody development, familiar with monoclonal antibody design strategies and immunological targeting approaches

Obviousness Rationale

A person skilled in the art would recognize that the Published Technical Disclosure represents predictable variations on the source patent's foundational antibody targeting approach, utilizing standard protein engineering techniques to extend the original invention's technical scope through routine optimization and application expansion strategies.

Obvious Combinations & Variations

Source Patent Element

Neutralizing antibody targeting S100A8/A9 heterodimer

PTD Variation

Extending targeting approach to additional inflammatory or disease contexts

Obviousness Reasoning

Applying known antibody targeting strategies to new disease applications represents a predictable extension using standard immunological design principles

Source Patent Element

Monoclonal antibody with specific subclass selection (IgG1-IgG4)

PTD Variation

Modifying antibody subclass to optimize therapeutic performance

Obviousness Reasoning

Selecting optimal antibody subclass for enhanced therapeutic efficacy is a routine design choice for skilled practitioners

Source Patent Element

Antibody fragment with heterodimer neutralization capability

PTD Variation

Developing alternative fragment configurations with improved binding characteristics

Obviousness Reasoning

Iterative antibody fragment engineering represents a standard approach for enhancing protein interaction specificity

Source Patent Element

Pharmaceutical composition targeting protein heterodimer

PTD Variation

Implementing novel delivery mechanisms or formulation strategies

Obviousness Reasoning

Exploring alternative pharmaceutical formulation techniques is an expected progression in therapeutic antibody development

Source Patent Element

Specific CDR region configuration for protein interaction

PTD Variation

Computational and experimental optimization of complementarity-determining regions

Obviousness Reasoning

Systematic CDR region modification represents a well-established technique for improving antibody binding specificity

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11858984, a person having ordinary skill in the art would find the variations disclosed herein to be obvious extensions of the prior art, representing predictable technical developments achievable through routine experimentation and standard protein engineering methodologies, thereby rendering potential derivative claims obvious and non-patentable under 35 U.S.C. § 103.

Original Patent Information

Patent Number	US 11,858,984
Title	Anti-S100A8/A9 antibody and use thereof
Assignee(s)	NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY, Niigata University